These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30309853)

  • 21. Hippocampal CCR5/RANTES Elevations in a Rodent Model of Post-Traumatic Stress Disorder: Maraviroc (a CCR5 Antagonist) Increases Corticosterone Levels and Enhances Fear Memory Consolidation.
    Merino JJ; Muñetón-Gomez V; Muñetón-Gómez C; Pérez-Izquierdo MÁ; Loscertales M; Toledano Gasca A
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32024104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High CD206 levels in Hodgkin lymphoma-educated macrophages are linked to matrix-remodeling and lymphoma dissemination.
    Arlt A; von Bonin F; Rehberg T; Perez-Rubio P; Engelmann JC; Limm K; Reinke S; Dullin C; Sun X; Specht R; Maulhardt M; Linke F; Bunt G; Klapper W; Vockerodt M; Wilting J; Pukrop T; Dettmer K; Gronwald W; Oefner PJ; Spang R; Kube D
    Mol Oncol; 2020 Mar; 14(3):571-589. PubMed ID: 31825135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.
    Aldinucci D; Casagrande N
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting Cancer Cells and Tumor Microenvironment in Preclinical and Clinical Models of Hodgkin Lymphoma Using the Dual PI3Kδ/γ Inhibitor RP6530.
    Locatelli SL; Careddu G; Serio S; Consonni FM; Maeda A; Viswanadha S; Vakkalanka S; Castagna L; Santoro A; Allavena P; Sica A; Carlo-Stella C
    Clin Cancer Res; 2019 Feb; 25(3):1098-1112. PubMed ID: 30352904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CCR5 antagonist maraviroc alleviates doxorubicin-induced neuroinflammation and neurobehavioral deficiency by regulating NF-κB/NLRP3 signaling in a breast cancer mouse model.
    Wu Y; Che J; Dong J; Zhang X; Deng Y; Chen W; Zhang J
    Neuropharmacology; 2024 Aug; 254():109981. PubMed ID: 38704022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential to target CCL5/CCR5 in breast cancer.
    Velasco-Velázquez M; Xolalpa W; Pestell RG
    Expert Opin Ther Targets; 2014 Nov; 18(11):1265-75. PubMed ID: 25256399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats.
    Kwiatkowski K; Piotrowska A; Rojewska E; Makuch W; Jurga A; Slusarczyk J; Trojan E; Basta-Kaim A; Mika J
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():68-78. PubMed ID: 26190414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel small-molecular CCR5 antagonist promotes neural repair after stroke.
    Wu QL; Cui LY; Ma WY; Wang SS; Zhang Z; Feng ZP; Sun HS; Chu SF; He WB; Chen NH
    Acta Pharmacol Sin; 2023 Oct; 44(10):1935-1947. PubMed ID: 37198412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
    Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
    Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel antagonist of the CCL5/CCR5 axis suppresses the tumor growth and metastasis of triple-negative breast cancer by CCR5-YAP1 regulation.
    Chen L; Xu G; Song X; Zhang L; Chen C; Xiang G; Wang S; Zhang Z; Wu F; Yang X; Zhang L; Ma X; Yu J
    Cancer Lett; 2024 Feb; 583():216635. PubMed ID: 38237887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of CCR5 on interstitial macrophages in the development of lung fibrosis in severe asthma.
    Matsuda M; Shimora H; Nagatani Y; Nishikawa K; Takamori I; Haguchi T; Kitatani K; Kaminuma O; Nabe T
    Int Immunopharmacol; 2024 Jun; 135():112331. PubMed ID: 38795597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational Engineering of a Sub-Picomolar HIV-1 Blocker.
    Secchi M; Vangelista L
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression.
    Xu J; Shi Q; Lou J; Wang B; Wang W; Niu J; Guo L; Chen C; Yu Y; Huang Y; Guo W; Lan J; Zhu Y; Ren T; Tang X
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37185233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A central role for glial CCR5 in directing the neuropathological interactions of HIV-1 Tat and opiates.
    Kim S; Hahn YK; Podhaizer EM; McLane VD; Zou S; Hauser KF; Knapp PE
    J Neuroinflammation; 2018 Oct; 15(1):285. PubMed ID: 30305110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The CCR5-antagonist Maraviroc reverses HIV-1 latency in vitro alone or in combination with the PKC-agonist Bryostatin-1.
    López-Huertas MR; Jiménez-Tormo L; Madrid-Elena N; Gutiérrez C; Rodríguez-Mora S; Coiras M; Alcamí J; Moreno S
    Sci Rep; 2017 May; 7(1):2385. PubMed ID: 28539614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of the chemokine receptor, CCR5, reduces the growth of orthotopically injected colon cancer cells via limiting cancer-associated fibroblast accumulation.
    Tanabe Y; Sasaki S; Mukaida N; Baba T
    Oncotarget; 2016 Jul; 7(30):48335-48345. PubMed ID: 27340784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In ovarian cancer maraviroc potentiates the antitumoral activity and further inhibits the formation of a tumor-promoting microenvironment by trabectedin.
    Casagrande N; Borghese C; Corona G; Aldinucci D
    Biomed Pharmacother; 2024 Mar; 172():116296. PubMed ID: 38382330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic Inhibition of R5 HIV-1 by the Fusion Protein (FLSC) IgG1 Fc and Maraviroc in Primary Cells: Implications for Prevention and Treatment.
    Latinovic OS; Zhang J; Tagaya Y; DeVico AL; Fouts TR; Schneider K; Lakowicz JR; Heredia A; Redfield RR
    Curr HIV Res; 2016; 14(1):24-36. PubMed ID: 26354735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CCL5/CCR5 axis contributes to the perineural invasion of human salivary adenoid cystic carcinoma.
    Shen Z; Li T; Chen D; Jia S; Yang X; Liang L; Chai J; Cheng X; Yang X; Sun M
    Oncol Rep; 2014 Feb; 31(2):800-6. PubMed ID: 24337063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CCR5 antagonist blocks metastasis of basal breast cancer cells.
    Velasco-Velázquez M; Jiao X; De La Fuente M; Pestell TG; Ertel A; Lisanti MP; Pestell RG
    Cancer Res; 2012 Aug; 72(15):3839-50. PubMed ID: 22637726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.